{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NF1+Mutation", "query": { "condition": "NF1 Mutation" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 23, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=NF1+Mutation&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T05:34:08.485Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02101736", "title": "Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NF1", "Neurofibromatosis", "Plexiform Neurofibromas" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 45, "start_date": "2014-06", "completion_date": "2022-02-16", "has_results": true, "last_update_posted_date": "2023-05-24", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 12, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02101736" }, { "nct_id": "NCT06961565", "title": "PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "NF1 Mutation", "Neurofibroma Plexiform", "Neurofibroma, Plexiform", "Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)", "Neurofibromatosis Type 1 (NF1)" ], "interventions": [ { "name": "PAS-004 Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pasithea Therapeutics Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 56, "start_date": "2025-05-30", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT06961565" }, { "nct_id": "NCT04166409", "title": "A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Low Grade Astrocytoma", "Low Grade Glioma", "Metastatic Low Grade Astrocytoma", "Metastatic Low Grade Glioma", "WHO Grade 1 Glioma", "WHO Grade 2 Glioma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Selumetinib Sulfate", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "21 Years", "sex": "ALL", "summary": "2 Years to 21 Years" }, "enrollment_count": 170, "start_date": "2020-01-31", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 124, "location_summary": "Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Loma Linda", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04166409" }, { "nct_id": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "PF-07284892", "type": "DRUG" }, { "name": "lorlatinib", "type": "DRUG" }, { "name": "binimetinib", "type": "DRUG" }, { "name": "cetuximab", "type": "BIOLOGICAL" }, { "name": "encorafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-03-17", "completion_date": "2024-06-19", "has_results": false, "last_update_posted_date": "2024-10-22", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 19, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Encinitas, California + 10 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "San Marcos", "state": "California" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT04800822" }, { "nct_id": "NCT06104488", "title": "A Study of Avutometinib for People With Solid Tumor Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Refractory Cancer", "CNS Tumors", "CNS Tumor, Adult", "CNS Tumor, Childhood", "MAP Kinase Family Gene Mutation", "NF1", "Plexiform Neurofibroma", "Low-grade Glioma", "Optic Pathway Gliomas", "Neuroblastoma", "Primary Brain Tumor", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "Central Nervous System Tumor" ], "interventions": [ { "name": "Avutometinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "3 Years to 30 Years" }, "enrollment_count": 23, "start_date": "2023-10-20", "completion_date": "2029-10-20", "has_results": false, "last_update_posted_date": "2026-02-25", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 2, "location_summary": "Atlanta, Georgia • New York, New York", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06104488" }, { "nct_id": "NCT04439318", "title": "Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lymphoma", "Advanced Malignant Solid Neoplasm", "Hematopoietic and Lymphoid Cell Neoplasm", "Refractory Lymphoma", "Refractory Malignant Solid Neoplasm", "Refractory Multiple Myeloma" ], "interventions": [ { "name": "Trametinib Dimethyl Sulfoxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2016-02-25", "completion_date": "2026-12-31", "has_results": true, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04439318" }, { "nct_id": "NCT02315625", "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Neuroendocrine Carcinoma", "Neuroendocrine Neoplasms", "Carcinoma, Neuroendocrine", "Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas" ], "interventions": [ { "name": "Sunitinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2015-04-08", "completion_date": "2019-05-22", "has_results": true, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02315625" }, { "nct_id": "NCT06287463", "title": "Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "RAF Mutation", "RAS Mutation", "NF1 Mutation", "Non-Small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Melanoma", "BRAF Gene Mutation", "CRAF Gene Mutation", "Castration-Resistant Prostate Cancer (CRPC)" ], "interventions": [ { "name": "DCC-3084", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Deciphera Pharmaceuticals, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-05-14", "completion_date": "2026-02-13", "has_results": false, "last_update_posted_date": "2026-03-05", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 9, "location_summary": "Los Angeles, California • San Francisco, California • Denver, Colorado + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06287463" }, { "nct_id": "NCT04395495", "title": "RASopathy Biorepository", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "RAS Mutation", "Neurofibromatosis 1", "Noonan Syndrome", "Noonan Syndrome With Multiple Lentigines", "Noonan Neurofibromatosis Syndrome", "Cardiofaciocutaneous Syndrome", "Costello Syndrome", "Legius Syndrome", "Smith-Kingsmore Syndrome", "MTOR Gene Mutation", "GATOR-1 Gene Mutation", "SYNGAP1-Related Intellectual Disability", "DLG4", "MAPK1 Gene Mutation" ], "interventions": [], "intervention_types": [], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2017-06-27", "completion_date": "2065-12", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04395495" }, { "nct_id": "NCT06299839", "title": "PAS-004 in Patients With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "RAS Mutation", "NF1 Mutation", "RAF Mutation", "Advanced Solid Tumors" ], "interventions": [ { "name": "PAS-004 Capsules", "type": "DRUG" }, { "name": "PAS-004 Tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pasithea Therapeutics Corp.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2024-02-29", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-05-22T05:34:08.485Z", "location_count": 4, "location_summary": "Austin, Texas • Irving, Texas • San Antonio, Texas + 1 more", "locations": [ { "city": "Austin", "state": "Texas" }, { "city": "Irving", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06299839" } ] }